Real‐life data regarding acute procedural success and 1‐year clinical outcome of desolve bioresorbable scaffolds

• Published in: Journal of interventional cardiology Vol. 30; no. 3; pp. 189 - 194
• Main Authors: Gunes, Haci Murat, Gokdeniz, Tayyar, Kizilirmak Yilmaz, Filiz, Demir, Gultekin Gunhan, Guler, Ekrem, Babur Guler, Gamze, Karaca, Oğuz, Cakal, Beytullah, Omaygenç, Mehmet Onur, İbişoğlu, Ersin, Boztosun, Bilal
• Format: Journal Article
• Language: English
• Published: United States Hindawi Limited 01.06.2017
• Subjects: Absorbable Implants - adverse effects; Aged; Cardiology; Clinical outcomes; Coronary Artery Disease - diagnosis; Coronary Artery Disease - surgery; Cross-Sectional Studies; Data processing; Desolve BRS; device success; Drug delivery; Drug-Eluting Stents - adverse effects; Female; Heart; Heart diseases; Humans; Immunosuppressive Agents - therapeutic use; Implants; Macrolides - therapeutic use; major cardiac events; Male; Middle Aged; Percutaneous Coronary Intervention - adverse effects; Percutaneous Coronary Intervention - instrumentation; Percutaneous Coronary Intervention - methods; Postoperative Complications - diagnosis; Postoperative Complications - epidemiology; Postoperative Complications - therapy; Reoperation - statistics & numerical data; Severity of Illness Index; Stents; Success; Thrombosis; Tissue Scaffolds - adverse effects; Treatment Outcome; major cardiac events; Desolve BRS; device success
• ISSN: 0896-4327; 1540-8183
• DOI: 10.1111/joic.12386

Objectives We aimed to evaluate the peri‐procedural success of DESolve bio‐resorbable scaffolds (BRSs) and analyzed real‐life data about major cardiac events during 1‐year follow‐up. Background There is little information about real‐life data of DESolve BRS which is a novel stent technology offering various advantages over drug eluting stents and commonly used in daily cardiology practice. Methods We conducted this single‐center and non‐randomized cross‐sectional study from June 2015 through August 2016 in Medipol University Department of Cardiology and included 117 patients undergoing single or multivessel percutaneous coronary interventions (PCI) with novolimus‐eluting BRS devices (152 scaffolds) (Elixir Medical Corporation). Study end points were acute device and procedural success, scaffold thrombosis and major adverse cardiac event (MACE) rates of DESolve BRS. Results Device success was 96.7% and procedural success was 99.3%. We detected MACE rate as 0.9% while clinical‐driven target lesion revascularization was performed in one patient. None of the patients experienced scaffold thrombosis or death. Peri‐procedural complications were reported in three patients. Conclusions High rates of successful scaffold implantations, low rates of peri‐procedural complications, and major cardiac events in long‐term suggest that DESolve scaffolds can safely and effectively be used in daily intervention practice by particularly experienced operators.